Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hextar Healthcare BhdXKLS:7803 +9.09% Debt-to-EBITDA is -0.35 as of Mar. 2026. The stock has 3 warning signs investors should review. Among 1,236 Chemicals companies, Hextar Healthcare Bhd ranks worse than 80906.07% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Hextar Healthcare Bhd's Debt-to-EBITDA or its related term are showing as below:
XKLS:7803'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.63 Med: 0.02 Max: 1.61
Current: -0.1
During the past 13 years, the highest Debt-to-EBITDA Ratio of Hextar Healthcare Bhd was 1.61. The lowest was -2.63. And the median was 0.02.
XKLS:7803's Debt-to-EBITDA is ranked worse than 100% of 1236
companies
in the Chemicals industry
Industry Median: 2.16
vs XKLS:7803: -0.10
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Hextar Healthcare Bhd Debt-to-EBITDA Related Terms
Hextar Healthcare Bhd Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Hextar Healthcare Bhd's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7803 vs LIN, SHW, ECL: Debt-to-EBITDA Comparison
For the Specialty Chemicals subindustry, Hextar Healthcare Bhd's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hextar Healthcare Bhd Debt-to-EBITDA vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Hextar Healthcare Bhd's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hextar Healthcare Bhd's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Hextar Healthcare Bhd (XKLS:7803) has a Debt-to-EBITDA of -0.35 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hextar Healthcare Bhd. According to the industry distribution chart, Hextar Healthcare Bhd ranks #999999 out of 1236 companies in the Chemicals industry.
Is Hextar Healthcare Bhd's Debt-to-EBITDA too high?
Hextar Healthcare Bhd's current Debt-to-EBITDA is -0.35. Based on the distribution chart, Hextar Healthcare Bhd ranks #999999 out of 1236 companies in the Chemicals industry, which is in the bottom quartile relative to peers.
How does Hextar Healthcare Bhd's Debt-to-EBITDA compare to LIN and SHW?
According to the Chemicals industry distribution chart, Hextar Healthcare Bhd ranks #999999 out of 1236 companies for Debt-to-EBITDA. This places Hextar Healthcare Bhd in the lower half of its industry. The industry median Debt-to-EBITDA is 2.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Chemicals company?
The median Debt-to-EBITDA among Chemicals companies is 2.16, based on 1,236 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hextar Healthcare Bhd. For the Chemicals industry, the median Debt-to-EBITDA is 2.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hextar Healthcare Bhd's current Debt-to-EBITDA is -0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hextar Healthcare Bhd stock overvalued right now?
Based on GuruFocus' analysis, Hextar Healthcare Bhd (XKLS:7803) is currently considered Possible Value Trap. The stock's GF Value™ is RM0.15, compared to a current price of RM0.06 — trading 60% below its estimated fair value. The current Debt-to-EBITDA is -0.35. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Hextar Healthcare Bhd (XKLS:7803), the current Debt-to-EBITDA is -0.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hextar Healthcare Bhd is principally involved in investment holding. Through its subsidiaries, it manufactures and sells rubber gloves. The company offers a wide range of industrial and safety gloves, household rubber gloves, and disposable vinyl and nitrile gloves. The company operates in three segments: Gloves operation, Medical devices operation, and Investment holding. The company generates the majority of its revenue from the Gloves operation segment. It has operations in Europe, Asia, North and South America, and the Rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7803 has been successfully added to your 
